Catalio Capital Management Portfolio

▤ Summary

Catalio Capital Management is highlighting Sidera Bio within its portfolio. Sidera Bio develops a metabolism, inflammation, and fibrosis modulator for chronic kidney disease and other fibrosis-related indications. The company says its lead program combines three drug mechanisms into one asset and is already in clinical trials for kidney and liver disease. Its platform also aims to identify therapeutic targets for cardiometabolic disease using genetic insights. This is a life sciences portfolio profile rather than a software product or company event.

▦ Linked Companies